TraumaPhase 4NCT04166877
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
A Phase 4 study testing Magnesium Sulfate in Parenteral Dosage Form in people with Trauma and Acute Pain, run by University of California, Davis at 1 site in United States.
Trial summary
Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Trauma, Acute Pain
- What is being tested?
- Magnesium Sulfate in Parenteral Dosage Form
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 156 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Dec 2019to 31 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All trauma patients admitted to an adult intensive care unit
- Signed informed consent
- Hospital or trauma multimodal pain management order set used for pain management
- Ages 18-99
Who cannot join
- Admission to the Pediatric Intensive Care Unit.
- Head Abbreviated Injury Score (AIS) of greater than 1
- Known heart failure with reduced ejection fraction (EF < 40%)
- Renal failure (GFR < 60)
- Cardiac arrhythmia (except for sinus tachycardia)
- Greater than 5% TBSA burn injuries
Show all 14Show fewer
- Moderate to severe alcohol withdrawal protocol ordered for patient
- Regular use of opioids in the week prior to injury
- Receiving continuous infusion of opioids
- Patients expected to require general anesthesia between 24 and 48 hours after admission (during study drug administration)
- Patients unable to provide consent is unavailable
- Patients unable to provide a pain score
- Pregnancy
- Prisoners
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UC Davis Health
Sacramento, California, 95817
Christine S Cocanour, MD
About this study
Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in decreasing narcotic (pain reliever) requirements and provide another non-narcotic drug for pain control.
The purpose of this study is to test the effectiveness of continuous, intravenous (into or within a vein using a needle) administration of magnesium sulfate for pain control in trauma patients admitted to the adult Intensive Care Unit. This will be compared to intravenous normal saline (salt solution).
Read the detailed description
This is a single center, double blind, randomized controlled study to demonstrate the effectiveness of continuous, intravenous administration of magnesium sulfate as compared to placebo in decreasing pain in critically injured patients.
Study Hypothesis The primary hypothesis is that continuous infusion magnesium sulfate will significantly decrease opioid requirements and pain scores in critically ill patients.
Background Magnesium is one of the most abundant cations in the human body. The physiologically active form of magnesium, ionized magnesium, is involved in hundreds of enzyme reactions that are important for homeostasis, action potentials, and membrane stability, among others.[Seo, et al] Hypomagnesemia is one of the most common electrolyte disturbances in the hospitalized patient, especially in the critically ill population. Studies have established that low magnesium levels increase mortality and morbidity in the critically ill patient,[Upala, et al] and thus magnesium is often repleted with intermittent infusion. Outside of its role in enzyme reactions, magnesium was discovered to have analgesic effects approximately twenty years ago.[Albrecht, et al] It appears to potentiate morphine analgesia, attenuate morphine tolerance, and suppress neuropathic pain.[Albrecht, et al] At a mechanistic level, these effects are thought to be secondary to magnesium regulating calcium influx into cells and antagonizing NMDA receptors in the central nervous system.
Magnesium has long been utilized in prevention and management of preeclampsia and eclampsia. A typical dosing regimen in this setting involves a 4 g loading dose of magnesium sulfate, followed by a magnesium infusion of 1-2 g/hr. When compared to eclampsia regimens, studies investigating the role of magnesium sulfate in multimodal surgical pain management consistently use lower doses. Even with this dosing, multiple trials have shown reduced postoperative pain and analgesic requirements.[Albrecht, et al, Sousa, et al, Hwang, et al, Shariat, et al] In one example, Shariat Moharari and others used a regimen of 40 mg/kg magnesium bolus followed by 10 mg/kg/hr infusion in perioperative gastrointestinal surgery patients, without adverse effects.[Shariat, et al]
Normal reference range for serum magnesium has been defined as approximately 0.7-1 mmol/L (1.5-2 mEq/L or 1.7-2.4 mg/dL).[Williamson, et al] Tramer et al. reported that a 3 g bolus dose of magnesium sulfate followed with 0.5 g/hr infusion for 20 hours resulted in an increase from baseline serum magnesium of approximately 0.6 mmol/L. Despite the higher post-treatment serum magnesium levels in the treatment group, no difference in safety outcomes was noted in comparison to the control group receiving 0.9% sodium chloride.[Tramer,et al] Similarly, Ozcan et al. found that 30 mg/kg bolus dose of magnesium sulfate followed by infusion of 10 mg/Kg/hr for 48 hours resulted in an increased serum magnesium level from baseline by approximately 0.7 mmol/L. The noted increase in serum magnesium level in this study also did not translate into any difference in safety endpoints between the intervention group and control group receiving 0.9% sodium chloride.[Ozcan, et al] Initial signs of magnesium toxicity following administration of magnesium sulfate have been reported to occur at serum magnesium levels greater than 3.5-5 mmol/L.[Lu, et al, Jahnen-Dechent, et al]
Despite the successful use of magnesium in perioperative pain management, it has yet to be applied in patient populations outside of the operating room. Given the need for adequate pain control among critically ill patients with traumatic injuries, the use of magnesium for pain management may assist in decreasing opioid requirements and provide another non-opioid adjunct for pain control.
Methods:
All trauma patients admitted to an adult ICU are screened during the first 24 hours after admission. If they meet criteria for admission to the study, an informed consent will be obtained. Patients meeting eligibility will be randomized by the Investigational Drug Service in a computer-generated, blinded block, 1:1 ratio to treatment with either magnesium sulfate (diluted appropriately in normal saline per standard procedures) or placebo (normal saline)."
Opioid administration will be recorded per usual nursing protocol in the electronic medial record. Heart rate, mean arterial pressure (MAP), respiratory rate, and RASS will be recorded at least every two hours per unit protocol.
A study worksheet will be posted at bedside for consistent collection of pain scores and CAM. Pain will be assessed per unit protocol using the numeric rating scale, with zero representing no pain and ten representing the worst pain imaginable.
The EMR will be reviewed; opioid administration, pain scores, and vital signs will be transferred to a separate data sheet through REDCap (Research Electronic Data Capture) software.
The primary outcome measure will be the total opioid requirement during the 24 hours of magnesium infusion. We performed this power analysis based on a recent retrospective cohort study performed at our institution.[Hamrick, et al] We estimate that the 24 hour OME requirement will decrease from 70 mg in the control group to 50 mg in the treatment group, with a standard deviation of 50 mg in each group, leading to an effect size of 0.4. Using the statistical program G*Power 3.0.1 with an effect size of 0.4, alpha of 0.05, power of 0.8, and equal allocation ratios, a sample size of 78 patients per group would be required.
Data will be assessed for normality by assessing distribution skewness and kurtosis. Depending on these results, t-tests or Wilcoxon rank-sum tests for two groups will be used to assess the primary outcome of total opioid dose. Other data, including pain scores, that is collected repeatedly will be analyzed with two-way repeated measures analysis of variance, with subsequent pair-wise comparison for any significant findings. Statistical significance will be set at a P value of less than 0.05. We will use SAS to perform the statistical analysis.
- Conditions
- Trauma, Acute Pain
- Being tested
- Magnesium Sulfate in Parenteral Dosage Form, Normal saline placebo
- Keywords
- magnesium sulfate, trauma, acute pain
- Medical subject headings
- Wounds and Injuries, Acute Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium Sulfate in Parenteral Dosage FormDrug
IV bolus followed by continuous infusion for 24 hours
Normal saline placeboDrug
IV bolus followed by continuous infusion for 24 hours
| Study group | Role | What they receive |
|---|---|---|
| Magnesium Group | Experimental | The magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours. Receives: Drug: Magnesium Sulfate in Parenteral Dosage Form |
| Control Group | Placebo comparator | The control arm will receive the same volume and rate of saline as if they were in the experimental group. Receives: Drug: Normal saline placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
total opioid requirements during study drug infusion
oral morphine equivalents, OME
Measured: 24 hours during study drug infusion
Secondary outcomes (9)
pain scores
numeric pain rating scale as reported by patient
Measured: daily x 4 days
Total oral morphine equivalents
Measured: daily x 4 days
ICU length of stay
Measured: through the patient's hospitalization for this injury, an average of 10 days
ICU-free days
14 days minus the number of ICU days
Measured: 14 days
Hospital length of stay
Measured: through the patient's hospitalization for this injury, an average of 10 days
Development of bradycardia
Measured: 24 hours during study drug infusion
Development of other dysrhythmia
Measured: 24 hours during study drug infusion
Respiratory depression
Episodes of respiratory depression as measured by a respiratory rate less than 8
Measured: 24 hours during study drug infusion
Prevalence of Richmond Agitation-Sedation Scale of -3 to -5
Episodes of a -3 to -5 Richmond Agitation-Sedation Scale score
Measured: 24 hours during study drug infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2019
- Study start7 Dec 2019
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for TraumaStudies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Single center, investigator-initiated, randomized, double-blinded, placebo controlled study
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 156 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04166877
- Sponsor's protocol ID
- 1440730
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2019
- Last updated
- 26 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Seo JW, Park TJ. Magnesium metabolism. Electrolyte Blood Press. 2008 Dec;6(2):86-95. doi: 10.5049/EBP.2008.6.2.86. Epub 2008 Dec 31.
PubMed 24459527Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. QJM. 2016 Jul;109(7):453-459. doi: 10.1093/qjmed/hcw048. Epub 2016 Mar 24.
PubMed 27016536Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1.
PubMed 23121612Sousa AM, Rosado GM, Neto Jde S, Guimaraes GM, Ashmawi HA. Magnesium sulfate improves postoperative analgesia in laparoscopic gynecologic surgeries: a double-blind randomized controlled trial. J Clin Anesth. 2016 Nov;34:379-84. doi: 10.1016/j.jclinane.2016.05.006. Epub 2016 Jun 5.
PubMed 27687417Hwang JY, Na HS, Jeon YT, Ro YJ, Kim CS, Do SH. I.V. infusion of magnesium sulphate during spinal anaesthesia improves postoperative analgesia. Br J Anaesth. 2010 Jan;104(1):89-93. doi: 10.1093/bja/aep334.
PubMed 19933175Shariat Moharari R, Motalebi M, Najafi A, Zamani MM, Imani F, Etezadi F, Pourfakhr P, Khajavi MR. Magnesium Can Decrease Postoperative Physiological Ileus and Postoperative Pain in Major non Laparoscopic Gastrointestinal Surgeries: A Randomized Controlled Trial. Anesth Pain Med. 2013 Dec 6;4(1):e12750. doi: 10.5812/aapm.12750. eCollection 2014 Feb.
PubMed 24660146Hamrick KL, Beyer CA, Lee JA, Cocanour CS, Duby JJ. Multimodal Analgesia and Opioid Use in Critically Ill Trauma Patients. J Am Coll Surg. 2019 May;228(5):769-775.e1. doi: 10.1016/j.jamcollsurg.2019.01.020. Epub 2019 Feb 21.
PubMed 30797081Williamson M. A., Snyder L. M., Wallach J. B. Wallach's Interpretation of Diagnostic Tests. 9th. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. xvi, 1143.
Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.
PubMed 8602664Ozcan PE, Tugrul S, Senturk NM, Uludag E, Cakar N, Telci L, Esen F. Role of magnesium sulfate in postoperative pain management for patients undergoing thoracotomy. J Cardiothorac Vasc Anesth. 2007 Dec;21(6):827-31. doi: 10.1053/j.jvca.2006.11.013. Epub 2007 Feb 7.
PubMed 18068060Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000 Apr;38(4):305-14. doi: 10.2165/00003088-200038040-00002.
PubMed 10803454Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163.
PubMed 26069819
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- ClinicalTrials.gov ID
- NCT04166877
- Acronym / sponsor ID
- 1440730
- Conditions
- Trauma, Acute Pain
- Keywords
- magnesium sulfate, trauma, acute pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 156 participants (estimated)
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Study start
- 7 Dec 2019 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 18 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium that is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. However, this drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may assist in decreasing narcotic (pain reliever) requirements and provide another non-narcotic drug for pain control.
The purpose of this study is to test the effectiveness of continuous, intravenous (into or within a vein using a needle) administration of magnesium sulfate for pain control in trauma patients admitted to the adult Intensive Care Unit. This will be compared to intravenous normal saline (salt solution).
Detailed description
This is a single center, double blind, randomized controlled study to demonstrate the effectiveness of continuous, intravenous administration of magnesium sulfate as compared to placebo in decreasing pain in critically injured patients.
Study Hypothesis The primary hypothesis is that continuous infusion magnesium sulfate will significantly decrease opioid requirements and pain scores in critically ill patients.
Background Magnesium is one of the most abundant cations in the human body. The physiologically active form of magnesium, ionized magnesium, is involved in hundreds of enzyme reactions that are important for homeostasis, action potentials, and membrane stability, among others.[Seo, et al] Hypomagnesemia is one of the most common electrolyte disturbances in the hospitalized patient, especially in the critically ill population. Studies have established that low magnesium levels increase mortality and morbidity in the critically ill patient,[Upala, et al] and thus magnesium is often repleted with intermittent infusion. Outside of its role in enzyme reactions, magnesium was discovered to have analgesic effects approximately twenty years ago.[Albrecht, et al] It appears to potentiate morphine analgesia, attenuate morphine tolerance, and suppress neuropathic pain.[Albrecht, et al] At a mechanistic level, these effects are thought to be secondary to magnesium regulating calcium influx into cells and antagonizing NMDA receptors in the central nervous system.
Magnesium has long been utilized in prevention and management of preeclampsia and eclampsia. A typical dosing regimen in this setting involves a 4 g loading dose of magnesium sulfate, followed by a magnesium infusion of 1-2 g/hr. When compared to eclampsia regimens, studies investigating the role of magnesium sulfate in multimodal surgical pain management consistently use lower doses. Even with this dosing, multiple trials have shown reduced postoperative pain and analgesic requirements.[Albrecht, et al, Sousa, et al, Hwang, et al, Shariat, et al] In one example, Shariat Moharari and others used a regimen of 40 mg/kg magnesium bolus followed by 10 mg/kg/hr infusion in perioperative gastrointestinal surgery patients, without adverse effects.[Shariat, et al]
Normal reference range for serum magnesium has been defined as approximately 0.7-1 mmol/L (1.5-2 mEq/L or 1.7-2.4 mg/dL).[Williamson, et al] Tramer et al. reported that a 3 g bolus dose of magnesium sulfate followed with 0.5 g/hr infusion for 20 hours resulted in an increase from baseline serum magnesium of approximately 0.6 mmol/L. Despite the higher post-treatment serum magnesium levels in the treatment group, no difference in safety outcomes was noted in comparison to the control group receiving 0.9% sodium chloride.[Tramer,et al] Similarly, Ozcan et al. found that 30 mg/kg bolus dose of magnesium sulfate followed by infusion of 10 mg/Kg/hr for 48 hours resulted in an increased serum magnesium level from baseline by approximately 0.7 mmol/L. The noted increase in serum magnesium level in this study also did not translate into any difference in safety endpoints between the intervention group and control group receiving 0.9% sodium chloride.[Ozcan, et al] Initial signs of magnesium toxicity following administration of magnesium sulfate have been reported to occur at serum magnesium levels greater than 3.5-5 mmol/L.[Lu, et al, Jahnen-Dechent, et al]
Despite the successful use of magnesium in perioperative pain management, it has yet to be applied in patient populations outside of the operating room. Given the need for adequate pain control among critically ill patients with traumatic injuries, the use of magnesium for pain management may assist in decreasing opioid requirements and provide another non-opioid adjunct for pain control.
Methods:
All trauma patients admitted to an adult ICU are screened during the first 24 hours after admission. If they meet criteria for admission to the study, an informed consent will be obtained. Patients meeting eligibility will be randomized by the Investigational Drug Service in a computer-generated, blinded block, 1:1 ratio to treatment with either magnesium sulfate (diluted appropriately in normal saline per standard procedures) or placebo (normal saline)."
Opioid administration will be recorded per usual nursing protocol in the electronic medial record. Heart rate, mean arterial pressure (MAP), respiratory rate, and RASS will be recorded at least every two hours per unit protocol.
A study worksheet will be posted at bedside for consistent collection of pain scores and CAM. Pain will be assessed per unit protocol using the numeric rating scale, with zero representing no pain and ten representing the worst pain imaginable.
The EMR will be reviewed; opioid administration, pain scores, and vital signs will be transferred to a separate data sheet through REDCap (Research Electronic Data Capture) software.
The primary outcome measure will be the total opioid requirement during the 24 hours of magnesium infusion. We performed this power analysis based on a recent retrospective cohort study performed at our institution.[Hamrick, et al] We estimate that the 24 hour OME requirement will decrease from 70 mg in the control group to 50 mg in the treatment group, with a standard deviation of 50 mg in each group, leading to an effect size of 0.4. Using the statistical program G*Power 3.0.1 with an effect size of 0.4, alpha of 0.05, power of 0.8, and equal allocation ratios, a sample size of 78 patients per group would be required.
Data will be assessed for normality by assessing distribution skewness and kurtosis. Depending on these results, t-tests or Wilcoxon rank-sum tests for two groups will be used to assess the primary outcome of total opioid dose. Other data, including pain scores, that is collected repeatedly will be analyzed with two-way repeated measures analysis of variance, with subsequent pair-wise comparison for any significant findings. Statistical significance will be set at a P value of less than 0.05. We will use SAS to perform the statistical analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Single center, investigator-initiated, randomized, double-blinded, placebo controlled study
| Arm | Type | Receives |
|---|---|---|
| Magnesium Group | Experimental | Drug: Magnesium Sulfate in Parenteral Dosage FormThe magnesium group arm will receive a 40 mg/kg IBW (maximum 4 g) bolus of intravenous magnesium sulfate, followed by a continuous infusion of 0.5 g/hr for a total of 24 hours. |
| Control Group | Placebo comparator | Drug: Normal saline placeboThe control arm will receive the same volume and rate of saline as if they were in the experimental group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- All trauma patients admitted to an adult intensive care unit
- Signed informed consent
- Hospital or trauma multimodal pain management order set used for pain management
- Ages 18-99
Key exclusion criteria (14 listed)
- Admission to the Pediatric Intensive Care Unit.
- Head Abbreviated Injury Score (AIS) of greater than 1
- Known heart failure with reduced ejection fraction (EF < 40%)
- Renal failure (GFR < 60)
- Cardiac arrhythmia (except for sinus tachycardia)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium Sulfate in Parenteral Dosage FormIV bolus followed by continuous infusion for 24 hours | Drug | Magnesium Group |
| Normal saline placeboIV bolus followed by continuous infusion for 24 hours | Drug | Control Group |
Primary outcome
total opioid requirements during study drug infusion
Time frame: 24 hours during study drug infusion
oral morphine equivalents, OME
9 secondary outcomes
pain scores
Time frame: daily x 4 days
Total oral morphine equivalents
Time frame: daily x 4 days
ICU length of stay
Time frame: through the patient's hospitalization for this injury, an average of 10 days
ICU-free days
Time frame: 14 days
Hospital length of stay
Time frame: through the patient's hospitalization for this injury, an average of 10 days
Development of bradycardia
Time frame: 24 hours during study drug infusion
Development of other dysrhythmia
Time frame: 24 hours during study drug infusion
Respiratory depression
Time frame: 24 hours during study drug infusion
Prevalence of Richmond Agitation-Sedation Scale of -3 to -5
Time frame: 24 hours during study drug infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2025.
- Background: PubMed 24459527Seo JW, Park TJ. Magnesium metabolism. Electrolyte Blood Press. 2008 Dec;6(2):86-95. doi: 10.5049/EBP.2008.6.2.86. Epub 2008 Dec 31.
- Background: PubMed 27016536Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. QJM. 2016 Jul;109(7):453-459. doi: 10.1093/qjmed/hcw048. Epub 2016 Mar 24.
- Background: PubMed 23121612Albrecht E, Kirkham KR, Liu SS, Brull R. Peri-operative intravenous administration of magnesium sulphate and postoperative pain: a meta-analysis. Anaesthesia. 2013 Jan;68(1):79-90. doi: 10.1111/j.1365-2044.2012.07335.x. Epub 2012 Nov 1.
- Background: PubMed 27687417Sousa AM, Rosado GM, Neto Jde S, Guimaraes GM, Ashmawi HA. Magnesium sulfate improves postoperative analgesia in laparoscopic gynecologic surgeries: a double-blind randomized controlled trial. J Clin Anesth. 2016 Nov;34:379-84. doi: 10.1016/j.jclinane.2016.05.006. Epub 2016 Jun 5.
- Background: PubMed 19933175Hwang JY, Na HS, Jeon YT, Ro YJ, Kim CS, Do SH. I.V. infusion of magnesium sulphate during spinal anaesthesia improves postoperative analgesia. Br J Anaesth. 2010 Jan;104(1):89-93. doi: 10.1093/bja/aep334.
- Background: PubMed 24660146Shariat Moharari R, Motalebi M, Najafi A, Zamani MM, Imani F, Etezadi F, Pourfakhr P, Khajavi MR. Magnesium Can Decrease Postoperative Physiological Ileus and Postoperative Pain in Major non Laparoscopic Gastrointestinal Surgeries: A Randomized Controlled Trial. Anesth Pain Med. 2013 Dec 6;4(1):e12750. doi: 10.5812/aapm.12750. eCollection 2014 Feb.
- Background: PubMed 30797081Hamrick KL, Beyer CA, Lee JA, Cocanour CS, Duby JJ. Multimodal Analgesia and Opioid Use in Critically Ill Trauma Patients. J Am Coll Surg. 2019 May;228(5):769-775.e1. doi: 10.1016/j.jamcollsurg.2019.01.020. Epub 2019 Feb 21.
- BackgroundWilliamson M. A., Snyder L. M., Wallach J. B. Wallach's Interpretation of Diagnostic Tests. 9th. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. xvi, 1143.
- Background: PubMed 8602664Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.
- Background: PubMed 18068060Ozcan PE, Tugrul S, Senturk NM, Uludag E, Cakar N, Telci L, Esen F. Role of magnesium sulfate in postoperative pain management for patients undergoing thoracotomy. J Cardiothorac Vasc Anesth. 2007 Dec;21(6):827-31. doi: 10.1053/j.jvca.2006.11.013. Epub 2007 Feb 7.
- Background: PubMed 10803454Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000 Apr;38(4):305-14. doi: 10.2165/00003088-200038040-00002.
- Background: PubMed 26069819Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163.
- Individual participant dataSharing planned: No
Related trials for Trauma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Not yet recruiting
Safety Study of Microlyte DualGuard
Wound Closure, Wound Care
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Magnesium Sulfate in Parenteral Dosage Form in people with Trauma and Acute Pain, run by University of California, Davis at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christine S Cocanour, MD (9167347330, cscocanour@ucdavis.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
total opioid requirements during study drug infusion (time frame: 24 hours during study drug infusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04166877, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2025.